Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 3/2006

Open Access 01-06-2006 | Report

Total body topical 5-fluorouracil for extensive non-melanoma skin cancer

Authors: Serge van Ruth, Frank G.A. Jansman, Cornelis J. Sanders

Published in: International Journal of Clinical Pharmacy | Issue 3/2006

Login to get access

Abstract

Background

Topical 5-fluorouracil 5% cream is one of␣the treatment modalities for non-melanoma skin cancer (NMSC). There is a lack of suitable therapies to treat patients with extensive NMSC. In this paper we report two patients with extensive NMSC treated by total body application of topical 5-fluorouracil 5% cream.

Observations

Topical 5-fluorouracil 5% cream was applied twice daily to the total body, including normal appearing skin. During the treatment, weekly blood samples were taken for measurement of 5-fluorouracil levels. All samples showed a 5-fluorouracil level less than the detection level of 10 µg/l. Total body 5-fluorouracil 5% cream was shown to be an effective treatment in our patients; the majority of lesions cleared in both patients.

Conclusions

In conclusion, total body topical 5-fluorouracil 5% cream application was successful in two patients with extensive NMSC. No detectable serum level of 5-fluorouracil could be determined. Pain and secondary infections were important side effects in our patients. However, in patients with extensive NMSC this treatment may be considered.
Literature
1.
go back to reference Chakrabarty A, Geisse JK. Medical therapies for non-melanoma skin cancer. Clin Dermatol 2004;22(3):183–8.CrossRefPubMed Chakrabarty A, Geisse JK. Medical therapies for non-melanoma skin cancer. Clin Dermatol 2004;22(3):183–8.CrossRefPubMed
2.
go back to reference Joulia JM, Pinguet F, Grosse PY, et al. Determination of 5-fluorouracil an its main metabolites in plasma by high-performance liquid chromatography: application to a pharmacokinetic study. J Chromatogr BBiomed Sci Appl 1997;692(2):427-5.CrossRef Joulia JM, Pinguet F, Grosse PY, et al. Determination of 5-fluorouracil an its main metabolites in plasma by high-performance liquid chromatography: application to a pharmacokinetic study. J Chromatogr BBiomed Sci Appl 1997;692(2):427-5.CrossRef
3.
go back to reference Reymann F. Treatment of basal cell carcinoma of the skin with 5-fluorouracil ointment. A 10-year follow-up study. Dermatologica 1979;158(50):368-2.CrossRefPubMed Reymann F. Treatment of basal cell carcinoma of the skin with 5-fluorouracil ointment. A 10-year follow-up study. Dermatologica 1979;158(50):368-2.CrossRefPubMed
4.
go back to reference Tutrone WD, Saini R, Caglar S, Weinberg JM, Crespo J. Topical therapy for actinic keratoses, I: 5-fluorouracil and imiquimod. Cutis 2003;71(5):365-0.PubMed Tutrone WD, Saini R, Caglar S, Weinberg JM, Crespo J. Topical therapy for actinic keratoses, I: 5-fluorouracil and imiquimod. Cutis 2003;71(5):365-0.PubMed
5.
go back to reference Hamouda B, Jamila Z, Najet R, et al. Topical 5-fluorouracil to treat multiple or unresectable facial squamous cell carcinomas in xeroderma pigmentosum. J Am Acad Dermatol 2001;44(6):1054.CrossRefPubMed Hamouda B, Jamila Z, Najet R, et al. Topical 5-fluorouracil to treat multiple or unresectable facial squamous cell carcinomas in xeroderma pigmentosum. J Am Acad Dermatol 2001;44(6):1054.CrossRefPubMed
6.
go back to reference Cartei G, Cartei F, Interlandi G, et al. Oral 5-fluorouracil in squamous cell carcinoma of the skin in the aged. Am J Clin Oncol 2000;23(2):181–4.CrossRefPubMed Cartei G, Cartei F, Interlandi G, et al. Oral 5-fluorouracil in squamous cell carcinoma of the skin in the aged. Am J Clin Oncol 2000;23(2):181–4.CrossRefPubMed
7.
go back to reference Hazen PG, Taub SJ. Basal cell nevus syndrome. Unresponsiveness of early cutaneous lesions to topical 5-fluorouracil or dinitrochlorobenzene. Dermatologica 1984;168(6):287–9.CrossRefPubMed Hazen PG, Taub SJ. Basal cell nevus syndrome. Unresponsiveness of early cutaneous lesions to topical 5-fluorouracil or dinitrochlorobenzene. Dermatologica 1984;168(6):287–9.CrossRefPubMed
8.
go back to reference Tsuji T, Otake N, Nishimura M. Cryosurgery and topical fluorouracil: a treatment method for widespread basal cell epithelioma in basal cell nevus syndrome. J Dermatol 1993;20(8):507-3.PubMed Tsuji T, Otake N, Nishimura M. Cryosurgery and topical fluorouracil: a treatment method for widespread basal cell epithelioma in basal cell nevus syndrome. J Dermatol 1993;20(8):507-3.PubMed
9.
go back to reference Jorizzo J, Weiss J, Furst K, VandePol C, Levy SF. Effect of a 1-week treatment with 0.5% topical fluorouracil on occurrence of actinic keratosis after cryosurgery. Arch Dermatol 2004;140:813–6.CrossRefPubMed Jorizzo J, Weiss J, Furst K, VandePol C, Levy SF. Effect of a 1-week treatment with 0.5% topical fluorouracil on occurrence of actinic keratosis after cryosurgery. Arch Dermatol 2004;140:813–6.CrossRefPubMed
10.
go back to reference Sander CA, Pfeiffer C, Kligman AM, et al. Chemotherapy for disseminated actinic keratoses with 5-fluorouracil and isotretinoin. J Am Acad Dermatol 1997;36:236–8.CrossRefPubMed Sander CA, Pfeiffer C, Kligman AM, et al. Chemotherapy for disseminated actinic keratoses with 5-fluorouracil and isotretinoin. J Am Acad Dermatol 1997;36:236–8.CrossRefPubMed
11.
go back to reference Levy S, Furst K, Chern W. A pharmacokinetic evaluation of 0.5% and 5% fluorouracil topical cream in patients with actinic keratosis. Clin Ther 2001;23(6):908-0.CrossRefPubMed Levy S, Furst K, Chern W. A pharmacokinetic evaluation of 0.5% and 5% fluorouracil topical cream in patients with actinic keratosis. Clin Ther 2001;23(6):908-0.CrossRefPubMed
12.
go back to reference Rozenman Y, Gurewich J, Gotsman MS. Myocardial ischemia by topical use of 5-fluorouracil. Int J Cardiol 1995;49(3):282–3.CrossRefPubMed Rozenman Y, Gurewich J, Gotsman MS. Myocardial ischemia by topical use of 5-fluorouracil. Int J Cardiol 1995;49(3):282–3.CrossRefPubMed
13.
go back to reference Johnson MR, Hageboutros A, Wang K, High L, Smith JF, Diasio RB. Life-threatening toxicity in a hihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil. Clin Cancer Res 1999;5(8):2006-1.PubMed Johnson MR, Hageboutros A, Wang K, High L, Smith JF, Diasio RB. Life-threatening toxicity in a hihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil. Clin Cancer Res 1999;5(8):2006-1.PubMed
14.
go back to reference Farrar CW, Bell HK, King CM. Allergic contact dermatitis from propylene glycol in Efudix cream. Contact Dermatitis 2003;48(6):345.CrossRefPubMed Farrar CW, Bell HK, King CM. Allergic contact dermatitis from propylene glycol in Efudix cream. Contact Dermatitis 2003;48(6):345.CrossRefPubMed
Metadata
Title
Total body topical 5-fluorouracil for extensive non-melanoma skin cancer
Authors
Serge van Ruth
Frank G.A. Jansman
Cornelis J. Sanders
Publication date
01-06-2006
Publisher
Springer Netherlands
Published in
International Journal of Clinical Pharmacy / Issue 3/2006
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-006-9030-x

Other articles of this Issue 3/2006

International Journal of Clinical Pharmacy 3/2006 Go to the issue

Editorial

Editorial